Current approaches to eradicate the drug-resistant cancer cell population include differentiation of CSCs, targeting of drug efflux proteins and other CSC surface markers, and inhibiting signaling pathways that maintain CSCs (Yang et al., 2020). This evidence concerns the gene PROS1 and cancer.